Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-stratified Therapy for AML and MDS (AMLCG 99)
NCT00266136Phase 3Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Jun 1999
- Primary completion
- Jan 2007
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cytarabine, filgrastim in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Universitätsklinikum Münster. Started Jun 1999; status: completed.
02
Drugs
cytarabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00266136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266136.